We rely on peer-reviewed scientific research to determine what’s truly effective. Our goal is to provide clear, unbiased information to help you make better health decisions.
We use AI tools to help summarize studies, and every piece of content is reviewed and approved by qualified experts, ensuring it’s accurate and trustworthy.
Beta Glucan is fully independent — we don’t sell products, run ads, or accept sponsorships. Our only focus is delivering reliable, science-backed insights.
Key study details
Objective
To review the therapeutic potential of medicinal mushrooms in brain cancer treatment, focusing on their immunomodulatory, cytotoxic, and supportive effects, and to present a case study illustrating their integrative use alongside conventional therapies.
Methods
This narrative review synthesizes findings from in vitro, in vivo, and clinical studies on various medicinal mushroom species and their bioactive compounds. It includes a case study of a glioblastoma patient treated with a daily oral regimen of Ganoderma lucidum, Agaricus blazei, Grifola frondosa, and Polyporus umbellatus in combination with standard radiochemotherapy.
Results
- Ganoderma lucidum polysaccharides (GL-PS) inhibited glioma growth and enhanced dendritic cell maturation, increasing IL-2, TNF-α, and IFN-γ.
- Maitake D-fraction improved hematologic parameters and synergized with chemotherapy.
- Cordycepin (from Cordyceps militaris) induced apoptosis and inhibited glioblastoma cell migration.
- Betulinic acid (from Inonotus obliquus) and polysaccharides from Trametes versicolor and Schizophyllum commune showed cytotoxic and antiviral effects.
- Hericium erinaceus extracts promoted neurite outgrowth and NGF expression.
- Mushroom extracts reduced chemotherapy-related side effects, including nausea, vomiting, fatigue, leukopenia, and appetite loss.
- In the case study, the patient showed reduced cerebral edema, decreased corticosteroid dependence, and improved imaging outcomes after two weeks of integrative mycotherapy.
Our take
Interpretation
Medicinal mushrooms offer multifaceted benefits in brain cancer care. Their bioactive compounds exert immunomodulatory, anti-inflammatory, and cytotoxic effects, potentially enhancing conventional therapies and improving patient outcomes. Mechanisms include cytokine modulation, dendritic cell activation, apoptosis induction, and neuroprotective signaling.
Limitations
- Most evidence is preclinical; human trials are limited and often non-randomized.
- Mechanistic pathways remain incompletely understood.
- Standardization of mushroom extracts and dosing is lacking.
- Integrative protocols vary widely across studies and clinical settings.
Implications
Medicinal mushrooms may serve as valuable adjuncts in integrative oncology for brain cancer. Their potential to modulate immunity, reduce treatment toxicity, and support neurological health warrants further clinical investigation. Collaboration between oncologists and mycotherapy practitioners is essential to optimize protocols and validate efficacy.
This summary is based on peer-reviewed scientific research. We use AI tools to help condense complex studies, but all content is reviewed and approved by qualified experts before publication.
Citation
Copied!